Literature DB >> 24085384

An update on liver surgery for cholangiocarcinoma.

Karim Boudjema1, Giovanni Battista Levi Sandri, Eveline Boucher, Tanguy Rohou, Michel Rayar, Laurent Sulpice.   

Abstract

Cholangiocarcinoma is a malignant neoplasm that originates from biliary epithelial cells. Complete tumor resection remains the most effective treatment of intra-hepatic or perihilar cholangiocarcinomas (PHCs). The objectives of this are to update and discuss methods that are likely to increase the resectability of cholangiocarcinomas, and to define the limits beyond which the risks of the treatments outweigh their benefits. We analyzed intra-hepatic cholangiocarcinomas and PHCs separately to determine the site of origin and the resectability of the tumor. We discussed the site at which to perform hepatic optimization prior to surgery, and whether liver transplantation might affect cholangiocarcinoma treatment.

Entities:  

Mesh:

Year:  2013        PMID: 24085384     DOI: 10.1007/s13304-013-0235-y

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  43 in total

1.  Klatskin tumors and the accuracy of the Bismuth-Corlette classification.

Authors:  Andreas Paul; Gernot M Kaiser; Ernesto P Molmenti; Tobias Schroeder; Spiridon Vernadakis; Arzu Oezcelik; Hideo A Baba; Vito R Cicinnati; Georgios C Sotiropoulos
Journal:  Am Surg       Date:  2011-12       Impact factor: 0.688

Review 2.  Liver transplantation for cholangiocarcinoma.

Authors:  Charles B Rosen; Julie K Heimbach; Gregory J Gores
Journal:  Transpl Int       Date:  2010-05-20       Impact factor: 3.782

Review 3.  Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature.

Authors:  M Shimoda; D G Farmer; S D Colquhoun; M Rosove; R M Ghobrial; H Yersiz; P Chen; R W Busuttil
Journal:  Liver Transpl       Date:  2001-12       Impact factor: 5.799

4.  Extent of liver resection for hilar cholangiocarcinoma.

Authors:  X-P Chen; W Y Lau; Z-Y Huang; Z-W Zhang; Y-F Chen; W-G Zhang; F-Z Qiu
Journal:  Br J Surg       Date:  2009-10       Impact factor: 6.939

5.  A simple system to predict perihilar cholangiocarcinoma resectability.

Authors:  Karim Boudjema; Laurent Sulpice; Sylvain Garnier; Jean-François Bretagne; Yves Gandon; Tanguy Rohou
Journal:  J Gastrointest Surg       Date:  2013-05-09       Impact factor: 3.452

6.  FDG-positron emission tomography/computed tomography and standardized uptake value in the primary diagnosis and staging of hilar cholangiocarcinoma.

Authors:  Anthony T Ruys; Roel J Bennink; Henderik L van Westreenen; Marc R Engelbrecht; Olivier R Busch; Dirk J Gouma; Thomas M van Gulik
Journal:  HPB (Oxford)       Date:  2011-03-07       Impact factor: 3.647

7.  Aggressive surgical resection for hilar cholangiocarcinoma of the left-side predominance: radicality and safety of left-sided hepatectomy.

Authors:  Hiroaki Shimizu; Fumio Kimura; Hiroyuki Yoshidome; Masayuki Ohtsuka; Atsushi Kato; Hideyuki Yoshitomi; Katsunori Furukawa; Masaru Miyazaki
Journal:  Ann Surg       Date:  2010-02       Impact factor: 12.969

8.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

9.  Surgical Approach for Long-term Survival of Patients With Intrahepatic Cholangiocarcinoma: A Multi-institutional Analysis of 434 Patients.

Authors:  Dario Ribero; Antonio Daniele Pinna; Alfredo Guglielmi; Antonio Ponti; Gennaro Nuzzo; Stefano Maria Giulini; Luca Aldrighetti; Fulvio Calise; Giorgio Enrico Gerunda; Mariano Tomatis; Marco Amisano; Pasquale Berloco; Guido Torzilli; Lorenzo Capussotti
Journal:  Arch Surg       Date:  2012-12

10.  Intrahepatic cholangiocarcinoma: impact of genetic hemochromatosis on outcome and overall survival after surgical resection.

Authors:  Laurent Sulpice; Michel Rayar; Eveline Boucher; Fabienne Pele; Marc Pracht; Bernard Meunier; Karim Boudjema
Journal:  J Surg Res       Date:  2012-11-20       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.